Previous studies have shown that approximately 90% of PCP occurs in patients with a CD4+ T cell count <200/μl (Helweg-Larsen et al., 1998), and the HIV-related guidelines have clearly recommended prophylactic treatment of PCP with a CD4+ T cell count < 200/μl as a level IA recommendation. This evidence concerns the gene CD4 and pneumocystosis.